In 2023, Kevin Sayer earned $16.73M in total compensation at DexCom, including $1.09M salary, $1.99M bonus and $13.51M in stock. Most recently sold 64,996 shares in Mar 2025. Currently holds stock worth $24.36M. Has donated $13.84M in stock to charitable causes. Has led DexCom for over 10 years.
Compensation History
Annual executive compensation data for Kevin Sayer, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$16.73M
Salary
$1.09M
Bonus
$1.99M
Other
$143.54K
Salary
$1.09MBoard Justification
The compensation philosophy is designed to attract and retain executive talent while aligning the interests of executives with those of stockholders through performance-based incentives.
Bonus
$1.99MBoard Justification
Annual cash bonus awarded under the 2023 Bonus Plan based on the achievement of financial and individual performance objectives.
Other Compensation
$143.54KBoard Justification
Includes personal security arrangements and tax reimbursements related to the attendance of the CEO's spouse at company events.
Restricted Stock
Board Justification
Performance-based stock units (PSUs) that vested based on the achievement of the Corporate Performance Metric and Relative TSR Performance Metric for fiscal 2023.
Performance Metrics
The performance metrics for the CEO's compensation in 2023 included adjusted revenue, non-GAAP operating margin, and strategic operational goals.
Kevin Sayer
CEO of DexCom
Education
Master's Degree in Accounting and Information Systems, B.A. from Brigham Young University
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
Born
November 30, 1959 - 66 years ago
CEO of DexCom for
10 years 11 months (Jan 2015 - Present)
Previous Experience
Served as President of DexCom since June 2011; served as Chief Financial Officer of Biosensors International Group, Ltd.
Holdings
Track Kevin Sayer's stock holdings and portfolio value over time.
Total Stock Sold
$188.41M
$188.41M
3,449,879 DXCM shares
What if they kept their stock?
If Kevin Sayer didn't sell their stock, today they would have:
Extra DXCM3,449,879 shares worth $225.93M.
This is 19.92% and $37.52M more than what they got when they sold the stock.
Charitable Transactions
211,260 shares
DXCM
Recent Charitable Transactions
10,000 shares
DXCM
Jan 18, 2023
Charity
3,000 shares
DXCM
Nov 15, 2021
Charity
10,000 shares
DXCM
Mar 8, 2021
Charity
13,474 shares
DXCM
Mar 11, 2020
Charity
20,841 shares
DXCM
Aug 15, 2019
Charity
500 shares
DXCM
Dec 14, 2016
Charity
Insider Trading
Kevin Sayer's recent stock transactions, purchases, and sales filed with the SEC.
$4.57M
DXCM at $70.38/share
Mar 12, 2025
Sale
170,980 shares
DXCM
Mar 8, 2025
Received
$2.90M
DXCM at $86.91/share
Jan 28, 2025
Sale
68,503 shares
DXCM
Jan 28, 2025
Received
$6.87M
DXCM at $138.33/share
Apr 8, 2024
Sale
$10.79M
DXCM at $133.19/share
Mar 12, 2024
Sale
51,692 shares
DXCM
Mar 8, 2024
Received
$4.61M
DXCM at $123.63/share
Jan 12, 2024
Sale
$72.71
DXCM at $0.00/share
Jan 12, 2024
Received
$2.39M
DXCM at $114.64/share
Apr 3, 2023
Sale
Rivals
Compare Kevin Sayer with competitor CEOs and industry peers.
Joseph W. Dziedzic
CEO of Integer Holdings
2022 Compensation
Stock
$0.00
Salary
$1.23M
Bonus
$0.00
Other
$97.75K
Total Holdings
$77.20M
Robert B. Ford
CEO of Abbott
2024 Compensation
Stock
$8.57M
Salary
$1.50M
Bonus
$2.86M
Other
$619.00K
Total Holdings
$23.06M
Michael Levitz
CEO of Insulet
2023 Compensation
Stock
$0.00
Salary
$842.31K
Bonus
$2.03M
Other
$9.90K
Total Holdings
$6.55M